The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches

Macaluso, FS; Fries, W; Viola, A; Centritto, A; Cappello, M; Giuffrida, E; Privitera, AC; Piccillo, G; Magnano, A; Vinci, E; Vassallo, R; Trovatello, A; Belluardo, N; Giangreco, E; Camilleri, S; Garufi, S; Bertolami, C; Ventimiglia, M; Renna, S; Orlando, R; Rizzuto, G; Orlando, A

Macaluso, FS (corresponding author), Villa Sofia Cervello Hosp, Viale Strasburgo 233, I-90146 Palermo, Italy.

INFLAMMATORY BOWEL DISEASES, 2021; 27 (2): 182

Abstract

Background: No data on the recently introduced infliximab (IFX) biosimilar SB2 in inflammatory bowel disease (IBD) are available. Methods: The Sicilia......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索